For the treatment of idiopathic interstitial pneumonia. Idiopathic interstitial pneumonia is a rare disease with unknown etiology and similar clinical characteristics. In 2017, there were about 200,000 cases worldwide, 37,000 in the United States and 57,000 in China. Although idiopathic interstitial pneumonia is histologically divided into six subgroups, all are characterized by varying degrees of inflammation and fibrosis, and all cause dyspnea and typical radiographic abnormalities. There is currently no effective treatment for idiopathic interstitial pneumonia on the market, and patients can only rely on extensive use of glucocorticoids as an alternative therapy to stay alive. Long-term glucocorticoid therapy not only has uncertain efficacy, but also can cause a series of side effects. Patients often end up needing lung transplants to save their lives. EG-001 has highly selective immunomodulatory and anti-inflammatory effects, and can enhance glucocorticoid sensitivity. Animal experiments show that EG-001 can inhibit lung inflammation, significantly inhibit pulmonary fibrosis and improve lung function. The global idiopathic interstitial pneumonia market is estimated to exceed US$4 billion.
EG-009 is an oral preparation for the treatment of cytokine storms caused by moderate to severe coronavirus pneumonia. Cytokine storm is a complex inflammatory response that is one of the major causes of death in COVID-19 patients. Cytokine storm occurs when levels of multiple cytokines are significantly elevated, eventually leading to acute respiratory distress syndrome and multiple organ failure. Cytokine storms can be caused not only by viral infections, but also after organ transplantation, macromolecular drug therapy, and CAR T cell therapy. EG-009 oral drug will mainly be used to treat cytokine storms in hospitalized COVID-19 patients. According to the latest statistics from the World Health Organization, more than 200 million people worldwide will be infected and 4.5 million will die by September 2021, so the development of a drug to treat COVID-19 is urgent.
EG-007 is an injectable drug used to treat endometrial cancer. Endometrial cancer is an epithelial malignant tumor occurring in the endometrium and is one of the three malignant tumors of female reproductive system. In 2020, there were about 420,000 new cases in the world, including about 80,000 cases in China and 60,000 cases in the United States. Endometrial cancer ranked first among female reproductive system tumors in the United States. Although immunotherapy drugs account for more than 60% of clinical trials in endometrial cancer, the low response rate of immune checkpoint drugs is an urgent problem to be solved in clinical practice. Animal experiments showed that EG-007 could enhance the therapeutic effect of anti-PD-1 /L1 antibody, which was related to enhancing the infiltration of CD8+ T cells, up-regulating IFN-γ signaling pathway, and improving the immunosuppressive microenvironment in tumor tissues. Our goal is to develop EG-007 in combination with immunotherapy as a first-line treatment for advanced endometrial cancer.
EG-101 is an injectable drug used to treat preeclampsia. Preeclampsia, which affects 2% to 7% of pregnancies in developed countries, is a major clinical complication of maternal and infant mortality. It is characterized by hypertension, proteinuria, and damage to other organs, most commonly the liver and kidneys. The specific pathogenesis of preeclampsia is still unclear, and may be related to vascular endothelial dysfunction. There are currently no approved drugs on the market for the treatment and prevention of pre-eclampsia. EG-101 has shown good therapeutic effects in animal models of preeclampsia, with significant improvement in hypertension and proteinuria.
Focal segmental glomerulosclerosis (FSGS) is a disease in which scar tissue develops on the parts of the kidneys that filter waste from the blood (glomeruli). FSGS may cause non-specific signs and symptoms, including protein in the urine, elevated levels of creatinine, and swelling. FSGS is a serious condition that can lead to kidney failure, for which the only treatment options are dialysis or kidney transplant. It is estimated that the incidence of FSGS is between 1.4 and 21 cases per million population, about 7-10% of children and 20-30% of adult patients with nephrotic syndrome. FSGS is more common in adult males, and its incidence is 1.5- 2 times that of females. In the United States, about 40,000 people suffer from FSGS, and more than 5,400 people are diagnosed with FSGS every year.
EG-201 is an eye drop for the treatment of age-related macular degeneration. Data show that wet macular degeneration is responsible for 90% of age-related macular blindness, and switching to wet macular degeneration can lead to central vision loss within 10-14 days. The current treatment is to inject anti-VEGF drugs into the eyeball, but there is often a risk of side effects, and currently the use of intravitreal injection of large-molecule drugs is very expensive. Therefore, the market needs locally used small molecule eye drops with novel mechanisms to supplement or replace existing large molecule intravitreal injection drugs. EG-201 is an eye drop with a new chemical structure and a new mechanism of action. Animal experiments have also proved its therapeutic effect on wet macular degeneration.
EG-301 is used to treat patients over 50 years of age with intermediate dry age-related amacular degeneration (Dry AMD). At this stage, presence of numerous medium-sized drusen or at least one large druse (diameter greater than 125 micrometers) Mild to moderate pigment changes in the retinal pigment epithelium Possible mild vision loss, but most individuals may not notice any significant symptoms.
EG-301 will be an oral dosage form that has been shown to be effective and safe in animal studies with fewer side effects. In 2020, there were about 100 million patients with macular disease worldwide, of which dry macular disease accounted for about 90%. There is an absolute global clinical need for dry macular disease. There are currently no drugs on the market to treat this disease, and the market size of its drugs is about US$60 - 90 billion.
Diabetic retinopathy (DR) is a microvascular disorder occurring due to long term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. It is estimated that 4.1 million people aged 40 and over in the United States suffer from diabetic retinopathy, and one out of every 29 people suffers from this disease. In 2020, the global market value of diabetic retinopathy drugs will reach about 7.6 billion US dollars. It is estimated that the drug market will grow at a compound annual growth rate of 5.6% during 2021-2026.
Retinopathy of prematurity (ROP) is a potentially blinding eye disorder that primarily affects premature infants weighing about 2¾ pounds (1250 grams) or less that are born before 31 weeks of gestation (a full-term pregnancy has a gestation of 38–42 weeks. ROP is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. There are approximately 3.9 million infants born in the U.S. each year; of those, about 28,000 weigh 2¾ pounds or less. About 14,000–16,000 of these infants are affected by some degree of ROP.
Except surgical approaches to ROP, current medication for ROP are mainly intravitreal injection of VEGF inhibitors, but the drugs may cross the blood-brain barrier of the still underdeveloped preterm infant and enter the blood circulation, causing potential adverse effects on the systemic system in which the preterm infant is growing and developing.
EG-501 is a small molecule tablet for the treatment of Cognitive Impairment (CI) in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disorder with a wide array of etiologies and exacerbations. Cognitive impairment is one of the most common manifestations. Examples of cognitive dysfunction include fog, memory impairment, aphasia, trouble with verbal recall, and difficulty with concentration. 56% of SLE patient likely to experience CI over one year. There is currently no drug specific for the treatment of cognitive impairment in NPSLE patients worldwide.